Clinical trial
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
NCT04310592 is registered in ClinicalTrials.gov with Celularity Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) with or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) or Relapsed/refractory (R/R) AML
- Lead sponsor
- Celularity Incorporated
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- March 12, 2020
- Completion date
- April 28, 2023
- Enrollment
- 27 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.
alkylating agents, analgesics, analgesics, non-narcotic, anti-infective agents, antimetabolites, antineoplastic, antiviral agents, hematologic diseases, hematologic neoplasms, immunologic factors, immunosuppressive agents, leukemia, leukemia in remission, leukemia, myeloid, leukemia, myeloid, acute, neoplasms, neoplasms by histologic type, peripheral nervous system agents, physiological effects of drugs, refractory aml, relapsed adult aml